Niall O'Donnell
Founder chez RENEO PHARMACEUTICALS, INC.
Fortune : - $ au 31/03/2024
Profil
Niall joined RiverVest in 2006 as a Kauffman Fellow and became a Managing Director in 2014.
He focuses on biopharmaceutical opportunities, building and operating RiverVest portfolio companies.
Niall is a co-founder and board member of Reneo Pharmaceuticals (NASDAQ: RPHM) and Mirum Pharmaceuticals, (NASDAQ: MIRM), and a board member of Avalyn Pharma, Glycomine, Inc., Sparrow Pharmaceuticals, and Spruce Biosciences ( NASDAQ: SPRB).
He was interim CEO of Reneo Pharmaceuticals, and was interim chief medical officer at Lumena Pharmaceuticals, prior to the company’s acquisition by Shire Plc (now part of Takeda America Holdings) in 2014.
Niall also helped co-found and seed Excaliard Pharmaceuticals, Inc., developing the company’s clinical strategy.
The company was subsequently acquired by Pfizer, Inc.
Prior to joining RiverVest, Niall spent five years as an immunologist at Johnson & Johnson Pharmaceutical Research and Development in San Diego.
He co-authored the first paper validating the newly-discovered histamine H4 receptor as a key regulator of immune pathologies.
Niall was also a member of the scientific advisory board of Ziarco Ltd., a developer of H4 receptor antagonists.
Ziarco was acquired by Novartis International AG in 2016.
Niall earned a Ph.D.
in Biochemistry from the University of Dundee, Scotland, and an M.A.
in Biochemistry from Pembroke College, Oxford.
He also received an M.B.A.
from the Rady School of Management of the University of California, San Diego.
His professional affiliations include the American Thoracic Society and American Association of Immunologists.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 06/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 | |
| 17/04/2023 | 0 ( -.--% ) | - $ | 31/03/2024 | |
SPRUCE BIOSCIENCES, INC.
-.--% | 25/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Niall O'Donnell
| Sociétés | Poste | Début |
|---|---|---|
| SPRUCE BIOSCIENCES, INC. | Director/Board Member | 01/05/2016 |
| RENEO PHARMACEUTICALS, INC. | Founder | - |
Lyric Pharmaceuticals, Inc.
 Lyric Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lyric Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company. The firm develops novel gastrointestinal therapeutics for unmet medical needs in the hospital settings. The company was founded by David Wurtman and M. Scott Harris in 2013 and is headquartered in South San Fancisco, CA. | Director/Board Member | - |
Glycomine, Inc.
 Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | Director/Board Member | - |
Sparrow Pharmaceuticals, Inc.
 Sparrow Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sparrow Pharmaceuticals, Inc. engages in pharmaceuticals industry. It develops drugs for cushing?s syndrome. The company was founded by David A. Katz and is headquartered in Portland, OR. | Director/Board Member | - |
Amplyx Pharmaceuticals, Inc.
 Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | Director/Board Member | - |
Avalyn Pharma, Inc.
 Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | Director/Board Member | 15/05/2017 |
RiverVest Venture Management LLC
 RiverVest Venture Management LLC Investment ManagersFinance RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Thomas Melzer, Craig Andrew and Jay Schmelter. The firm is headquartered in St. Louis, Missouri. | Private Equity Investor | 01/01/2008 |
Anciens postes connus de Niall O'Donnell
| Sociétés | Poste | Fin |
|---|---|---|
| MIRUM PHARMACEUTICALS, INC. | Founder | 12/06/2023 |
| ░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░░░░░ ░░░░░ ░░░░░░░ ░░░░░░░░░░░░░░ ░░░░░░░░ ░░░░░ ░░░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formation de Niall O'Donnell
| University Of Dundee | Doctorate Degree |
| Rady School of Management at UC San Diego | Masters Business Admin |
| Pembroke College Oxford | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| RENEO PHARMACEUTICALS, INC. | Health Technology |
| SPRUCE BIOSCIENCES, INC. | Health Technology |
| MIRUM PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 11 |
|---|---|
Lumena Pharmaceuticals, Inc.
 Lumena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lumena Pharmaceuticals, Inc. developed oral therapeutics for rare liver diseases. The firm was engaged in the development and commercialization of novel products for rare cholestatic liver diseases and serious metabolic disorders, such as nonalcoholic steatohepatitis. The company was founded by Bronislava Gedulin and Michael G. Grey in January 2011 and was headquartered in San Diego, CA. | Health Technology |
Avalyn Pharma, Inc.
Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | Health Technology |
Lyric Pharmaceuticals, Inc.
Lyric Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lyric Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company. The firm develops novel gastrointestinal therapeutics for unmet medical needs in the hospital settings. The company was founded by David Wurtman and M. Scott Harris in 2013 and is headquartered in South San Fancisco, CA. | Health Technology |
RiverVest Venture Management LLC
RiverVest Venture Management LLC Investment ManagersFinance RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Thomas Melzer, Craig Andrew and Jay Schmelter. The firm is headquartered in St. Louis, Missouri. | Finance |
Johnson & Johnson Pharmaceutical Research & Development LLC
 Johnson & Johnson Pharmaceutical Research & Development LLC Miscellaneous Commercial ServicesCommercial Services Johnson & Johnson Pharmaceutical Research & Development LLC provides research and development support services. It offers drug discovery and drug development in a variety of therapeutic areas, including CNS, Internal Medicine and Oncology, to address unmet medical needs worldwide. The company is headquartered in Raritan, NJ. | Commercial Services |
Excaliard Pharmaceuticals, Inc.
 Excaliard Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Excaliard Pharmaceuticals, Inc. manufactures, develops therapeutics for the treatment of scarring and fibrotic disorders. The company was founded by John Gordon Foulkes and Nicholas M. Dean in 2006 and is headquartered in New York, NY. | Health Technology |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | Health Technology |
Ziarco Group Ltd.
 Ziarco Group Ltd. Pharmaceuticals: MajorHealth Technology Ziarco Group Ltd. operates as a clinical-stage biotechnology company that develops therapeutics targeting inflammatory skin diseases. The firm engages in development of novel treatments in dermatology. The company was incorporated on March 10, 2014 and is headquartered in Canterbury, the United Kingdom. | Health Technology |
Glycomine, Inc.
Glycomine, Inc. BiotechnologyHealth Technology Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA. | Health Technology |
Curzion Pharmaceuticals, Inc.
 Curzion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Curzion Pharmaceuticals, Inc. operates as a pharmaceutical firm. The company is headquartered in San Diego, CA. | Health Technology |
Sparrow Pharmaceuticals, Inc.
Sparrow Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sparrow Pharmaceuticals, Inc. engages in pharmaceuticals industry. It develops drugs for cushing?s syndrome. The company was founded by David A. Katz and is headquartered in Portland, OR. | Health Technology |
